EYP-1901 for Wet Age-Related Macular Degeneration

EYP-1901 for Wet Age-Related Macular Degeneration
51%40%29%May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 27 • YES 39.5%
EyePoint Pharmaceuticals, Inc. ($EYPT)
No stock close$13.61$12.52$11.44May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 18 • EYPT $11.70May 19 • EYPT $11.82May 20 • EYPT $12.50May 21 • EYPT $12.78May 22 • EYPT $12.93May 26 • EYPT $13.35May 27 • EYPT $13.16

Will this trial show a positive result on Average change in best corrected visual acuity (BCVA), Weeks 52 and 56?

Paper Trading
Create account to trade
Scientific editorial illustration for Wet Age-Related Macular Degeneration

Wet Age-Related Macular Degeneration

Wet age-related macular degeneration damages the macula, causing blurred or distorted central vision in older adults. Trials track best corrected vision, meaning letters read with glasses, because it reflects reading, faces, and driving sight.